

Giorgio Valabrega

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/212515/giorgio-valabrega-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

68

papers

1,359

citations

21

h-index

35

g-index

75

ext. papers

1,713

ext. citations

5.3

avg, IF

4.63

L-index

#	Paper	IF	Citations
68	Ovarian Cancer Cells in Ascites Form Aggregates That Display a Hybrid Epithelial-Mesenchymal Phenotype and Allows Survival and Proliferation of Metastasizing Cells.. <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3	3
67	From Uterus to Brain: An Update on Epidemiology, Clinical Features, and Treatment of Brain Metastases From Gestational Trophoblastic Neoplasia.. <i>Frontiers in Oncology</i> , 2022 , 12, 859071	5.3	0
66	Cancer Cells Haploinsufficient for ATM Are Sensitized to PARP Inhibitors by MET Inhibition. <i>International Journal of Molecular Sciences</i> , 2022 , 23, 5770	6.3	0
65	Differences in PARP Inhibitors for the Treatment of Ovarian Cancer: Mechanisms of Action, Pharmacology, Safety, and Efficacy. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	13
64	Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: a retrospective MITO group study. <i>International Journal of Gynecological Cancer</i> , 2021 , 31, 1031-1036	3.5	1
63	SIENDO/ENGOT-EN5/GOG-3055: A randomized phase 3 trial of maintenance selinexor versus placebo after combination platinum-based chemotherapy in advanced or recurrent endometrial cancer.. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS5610-TPS5610	2.2	1
62	Characteristics and outcome of BRCA mutated epithelial ovarian cancer patients in Italy: A retrospective multicenter study (MITO 21). <i>Gynecologic Oncology</i> , 2021 , 161, 755-761	4.9	3
61	The Role of PARP Inhibitors in the Ovarian Cancer Microenvironment: Moving Forward From Synthetic Lethality. <i>Frontiers in Oncology</i> , 2021 , 11, 689829	5.3	4
60	Impact of COVID-19 on medical treatment patterns in gynecologic oncology: a MITO group survey. <i>International Journal of Gynecological Cancer</i> , 2021 , 31, 1363-1368	3.5	0
59	Biomarkers of Central Nervous System Involvement from Epithelial Ovarian Cancer.. <i>Cells</i> , 2021 , 10,	7.9	1
58	Validation of Androgen Receptor loss as a risk factor for the development of brain metastases from ovarian cancers. <i>Journal of Ovarian Research</i> , 2020 , 13, 53	5.5	3
57	Clinical Implications of DNA Repair Defects in High-Grade Serous Ovarian Carcinomas. <i>Cancers</i> , 2020 , 12,	6.6	7
56	Immune Checkpoint Inhibitors in Epithelial Ovarian Cancer: An Overview on Efficacy and Future Perspectives. <i>Diagnostics</i> , 2020 , 10,	3.8	24
55	Immuno-Metabolism and Microenvironment in Cancer: Key Players for Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	31
54	Is an Actionable Mutation in High Grade Serous Ovarian Carcinoma. <i>Cells</i> , 2020 , 9,	7.9	3
53	Impact of COVID-19 in gynecologic oncology: a Nationwide Italian Survey of the SIGO and MITO groups. <i>Journal of Gynecologic Oncology</i> , 2020 , 31, e92	4	10
52	Long-lasting, irreversible and late-onset immune-related adverse events (irAEs) from immune checkpoint inhibitors (ICIs): A real-world data analysis.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e15095-e15095	2.2	0

51	Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome. <i>Gynecologic Oncology</i> , 2020 , 156, 38-44	4.9	27
50	Brain Metastases from Ovarian Cancer: Current Evidence in Diagnosis, Treatment, and Prognosis. <i>Cancers</i> , 2020 , 12,	6.6	13
49	Immunotherapy in cervix cancer. <i>Cancer Treatment Reviews</i> , 2020 , 90, 102088	14.4	12
48	Cytoreductive Surgery for Heavily Pre-Treated, Platinum-Resistant Epithelial Ovarian Carcinoma: A Two-Center Retrospective Experience. <i>Cancers</i> , 2020 , 12,	6.6	3
47	Ovarian Cancer Immunotherapy: Turning up the Heat. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	76
46	CAR-Based Strategies beyond T Lymphocytes: Integrative Opportunities for Cancer Adoptive Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	24
45	Role of Cyclin-Dependent Kinase Inhibitors in Endometrial Cancer. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	17
44	Veliparib: a new therapeutic option in ovarian cancer?. <i>Future Oncology</i> , 2019 , 15, 1975-1987	3.6	5
43	The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer. <i>Gynecologic Oncology</i> , 2019 , 153, 535-540	4.9	14
42	TOP2A as marker of response to pegylated liposomal doxorubicin (PLD) in epithelial ovarian cancers. <i>Journal of Ovarian Research</i> , 2019 , 12, 17	5.5	13
41	Women With Synchronous or Metachronous Lung and Ovarian Cancer: A Multi-Institutional Report. <i>In Vivo</i> , 2019 , 33, 2021-2026	2.3	1
40	Modeling ErbB2-p130Cas interaction to design new potential anticancer agents. <i>Scientific Reports</i> , 2019 , 9, 3089	4.9	2
39	Endometrial Cancer Stem Cells: Role, Characterization and Therapeutic Implications. <i>Cancers</i> , 2019 , 11,	6.6	30
38	Reprogramming T-cells for adoptive immunotherapy of ovarian cancer. <i>Expert Opinion on Biological Therapy</i> , 2018 , 18, 359-367	5.4	5
37	A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience. <i>Journal of Ovarian Research</i> , 2018 , 11, 42	5.5	16
36	PARP Inhibitors in Ovarian Cancer. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2018 , 13, 392-410	2.6	60
35	Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity. <i>Oncotarget</i> , 2017 , 8, 90532-90544	3.3	60
34	Androgen receptor status predicts development of brain metastases in ovarian cancers. <i>Oncotarget</i> , 2017 , 8, 41143-41153	3.3	8

33	New and developing chemical pharmacotherapy for treating hormone receptor-positive/HER2-negative breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 2179-2189 ⁴		9
32	p130Cas scaffold protein regulates ErbB2 stability by altering breast cancer cell sensitivity to autophagy. <i>Oncotarget</i> , 2016 , 7, 4442-53	3.3	8
31	Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer. <i>Oncotarget</i> , 2016 , 7, 26181-91	3.3	13
30	Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer?. <i>International Journal of Molecular Sciences</i> , 2016 , 17,	6.3	41
29	Adoptive immunotherapy against ovarian cancer. <i>Journal of Ovarian Research</i> , 2016 , 9, 30	5.5	25
28	A retrospective analysis of the activity and safety of oral Etoposide in heavily pretreated metastatic breast cancer patients. <i>Breast Journal</i> , 2015 , 21, 241-5	1.2	10
27	Buparlisib , an oral pan-PI3K inhibitor for the treatment of breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2015 , 24, 421-31	5.9	23
26	Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer. <i>Molecular Oncology</i> , 2014 , 8, 20-6	7.9	34
25	Recent advances in the development of breast cancer vaccines. <i>Breast Cancer: Targets and Therapy</i> , 2014 , 6, 159-68	3.9	16
24	Overcoming endocrine resistance in metastatic breast cancer: Current evidence and future directions. <i>World Journal of Clinical Oncology</i> , 2014 , 5, 990-1001	2.5	73
23	Hormone-receptor expression and activity of trastuzumab with chemotherapy in HER2-positive advanced breast cancer patients. <i>Cancer</i> , 2012 , 118, 17-26	6.4	49
22	Omission of axillary dissection after a positive sentinel node dissection may influence adjuvant chemotherapy indications in operable breast cancer patients. <i>Annals of Surgical Oncology</i> , 2012 , 19, 3753-61 ^{3,1}		15
21	Potential of afatinib in the treatment of patients with HER2-positive breast cancer. <i>Breast Cancer: Targets and Therapy</i> , 2012 , 4, 131-7	3.9	11
20	Moderate immunohistochemical expression of HER-2 (2+) without HER-2 gene amplification is a negative prognostic factor in early breast cancer. <i>Oncologist</i> , 2012 , 17, 1418-25	5.7	35
19	Current status and future perspectives in the endocrine treatment of postmenopausal, hormone receptor-positive metastatic breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2012 , 13, 2143-56	4	6
18	Trastuzumab in the adjuvant setting: a practical review. <i>Therapy: Open Access in Clinical Medicine</i> , 2011 , 8, 161-177		
17	HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib. <i>Breast Cancer Research and Treatment</i> , 2011 , 130, 29-40	4.4	37
16	Hitting multiple targets in HER2-positive breast cancer: proof of principle or therapeutic opportunity?. <i>Expert Opinion on Pharmacotherapy</i> , 2011 , 12, 549-65	4	7

15	Trastuzumab beyond progression in retrospective analyses: an issue of equal opportunities. <i>Oncologist</i> , 2011 , 16, 534-6	5.7	1
14	Role of trastuzumab in the management of HER2-positive metastatic breast cancer. <i>Breast Cancer: Targets and Therapy</i> , 2010 , 2, 93-109	3.9	6
13	Underuse of anthracyclines in women with HER-2+ advanced breast cancer. <i>Oncologist</i> , 2010 , 15, 665-72	5.7	8
12	Trastuzumab beyond disease progression: case closed?. <i>Journal of Clinical Oncology</i> , 2009 , 27, e121-2; author reply e124-5	2.2	5
11	Multitarget drugs: the present and the future of cancer therapy. <i>Expert Opinion on Pharmacotherapy</i> , 2009 , 10, 589-600	4	53
10	Vinorelbine-based salvage therapy in HER2-positive metastatic breast cancer patients progressing during trastuzumab-containing regimens: a retrospective study. <i>BMC Cancer</i> , 2008 , 8, 209	4.8	8
9	Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era. <i>Clinical Breast Cancer</i> , 2008 , 8, 436-42	3	21
8	Trastuzumab-related cardiotoxicity in the herceptin adjuvant trial. <i>Journal of Clinical Oncology</i> , 2008 , 26, 2052-3; author reply 2053-4	2.2	10
7	Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity. <i>Expert Opinion on Biological Therapy</i> , 2007 , 7, 257-68	5.4	84
6	Recent advances in the medical management of breast cancer: highlights from the 29th San Antonio Breast Cancer Conference San Antonio, TX, USA, 14-17 December 2007. <i>Expert Opinion on Pharmacotherapy</i> , 2007 , 8, 1179-88	4	
5	Trastuzumab treatment in breast cancer. <i>New England Journal of Medicine</i> , 2006 , 354, 2186; author reply 2186	59.2	9
4	Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy. <i>Oncologist</i> , 2006 , 11, 318-24	5.7	105
3	Controversies in breast cancer: adjuvant and neoadjuvant therapy. <i>Expert Opinion on Pharmacotherapy</i> , 2005 , 6, 1055-72	4	5
2	TGFalpha expression impairs Trastuzumab-induced HER2 downregulation. <i>Oncogene</i> , 2005 , 24, 3002-10	9.2	101
1	Trastuzumab-based combination therapy for breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2004 , 5, 81-96	4	39